Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_assertion type Assertion NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_head.
- NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_assertion wasGeneratedBy ECO_0000203 NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_provenance.
- NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_assertion wasDerivedFrom befree-2016 NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_provenance.
- NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_assertion SIO_000772 21703428 NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_provenance.
- NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_assertion evidence source_evidence_literature NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_provenance.
- NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_assertion description "[Comparable in efficacy with Bevacizumab, monotherapy with the PAR1 i3 loop pepducin P1pal-7 provided significant 75% inhibition of lung tumor growth in nude mice.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP904815.RASLss0MwdXFfsTG7JA9ac9I2eHZwXn8jRnaDXypLxhrs130_provenance.